5-Amino-1MQ Reconstitution Calculator

No. 5-Amino-1MQ (5-amino-1-methylquinolinium, 5-AMQ) is a preclinical nicotinamide N-methyltransferase (NNMT) inhibitor with no published human trials; all efficacy data are rodent or cell-line studies,, (animal). It is not FDA-approved for any indication and is distributed as a research chemical. No validated prescription dose exists.

Rat pharmacokinetics: oral 5-AMQ achieved 38.4% bioavailability, peak plasma 2,252 ng/mL, and 6.9 h terminal half-life versus 3.8 h IV, with a linear assay range of 10–2,500 ng/mL (animal). Subcutaneous PK is unpublished. Community protocols use both routes: oral 50–150 mg/day, and subcutaneous 50–150 mg/day total (typically ~1 mg/kg), split 25–50 mg 2–3×/day (community protocol). Store lyophilized powder at -20°C; reconstitute with sterile/bacteriostatic water, refrigerate, and use within ~30 days (community protocol).

In diet-induced obese mice, 5-amino-1-methylquinolinium reduced body weight and white adipose mass, shrank adipocyte size, and lowered plasma cholesterol without changing food intake (animal). Combined with a lean-diet switch, it normalized body composition, liver weight, and hepatic steatosis to lean-control levels faster than diet switch alone (animal). No human fat-loss trials exist; the magnitude of human effects is unquantified.

Mouse efficacy dosing: 5 and 10 mg/kg/day systemic, both improving aged-muscle regeneration (animal). Allometric scaling of the 10 mg/kg dose to a 70 kg human is ~0.8 mg/kg (~57 mg/day), close to the low end of the community 50–150 mg/day oral range; some protocols extend to ~200 mg/day (community protocol). No human PK or safety data validate any dose.

Published animal courses: 1-week and 3-week post-injury regimens, plus a 2-month treatment window in aged mice, (animal). Community cycles commonly run 8–12 weeks (community protocol). Long-term human safety is unknown; NNMT inhibition raises cellular nicotinamide adenine dinucleotide (NAD+) and S-adenosylmethionine (SAM) pools, so extended unsupervised use carries unquantified risk.

No. No reproductive or developmental toxicology studies exist in any species. NNMT regulates NAD+ and SAM levels that underpin methylation-dependent development. Avoid during pregnancy, breastfeeding, and while attempting to conceive. Not studied in pediatric populations.

In aged (24-month) mice, NNMTi alone increased grip strength ~40% versus ~20% for exercise alone; combination was additive at ~60% (animal). NNMTi also reactivated senescent muscle stem cells, near-doubled regenerated fiber cross-sectional area, and raised peak torque ~70% after injury (animal). No human comparative data exist versus diet, exercise, or GLP-1-based programs.

Not clinically. NNMT inhibitors including 5-AMQ (together with 6MeONa and EL-1) reduced viability and triggered apoptosis via increased reactive oxygen species in osteosarcoma (U-2 OS, Saos-2) and Merkel cell carcinoma (MCC13, MCC26) lines, and enhanced cisplatin (in-vitro). The related methylquinolinium 5MQ inhibited HeLa cervical cancer proliferation concentration-dependently while sparing HEK-293 cells (in-vitro). Anticancer use is investigational; never substitute for oncology care.